Efficacy of Epratuzumab, an Anti ‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: Post‐hoc Analyses from the EMBODY Trials

ConclusionPatients with SLE and aSjS treated with epratuzumab showed improvements in SLE disease activity, which was associated with bioactivity, such as decreases in B cells and IgM.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatism - January 30, 2018 Category: Rheumatology Authors: Jacques ‐Eric Gottenberg, Thomas Dörner, Hendrika Bootsma, Valérie Devauchelle‐Pensec, Simon J. Bowman, Xavier Mariette, Holger Bartz, Marga Oortgiesen, Anthony Shock, Willem Koetse, Catrinel Galateanu, Sabine Bongardt, William A. Wegener, David M. Tags: Full Length Source Type: research